40 results on '"Mazzoni F"'
Search Results
2. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
3. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy
4. Determination of binding energy in molecular clusters by ion imaging methods: A test on the phenol–water 1:1 cluster
5. Predictors of rehospitalization in young adults with first episode psychosis – a comparison between LAI and oral antipsychotic therapy
6. Resistance or pseudo-resistance? An exploratory analysis in a sample of outpatients with treatment-resistant depression in an Italian mental health center
7. A comparison between lurasidone and other antipsychotics as add-on therapy to clozapine in treatment resistant schizophrenia: an observational study
8. EP.12H.05 Phase II Study on Platinum-Pemetrexed and Lorlatinib Combination in ALK-Positive NSCLC Extracranially Progressing on Lorlatinib
9. MA01.03 Neoadjuvant Alectinib in Potentially Resectable Stage III ALK-Positive NSCLC: Interim Analysis of ALNEO-GOIRC-01-2020 Phase II Trial
10. 1349P A prospective study on clinicians’ attitudes and survival outcomes for patients with NSCLC and poor performance status in the immunotherapy era: PICASO study (GOIRC-04-2020)
11. Phase II trial of single-agent oral vinorelbine in elderly (≥70 years) patients with advanced non-small-cell lung cancer and poor performance status
12. Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
13. EP07.04-06 ALK Rearrangement Is Associated with Early Lymphatic Spread in Resected LUAD with Negative Preoperative Mediastinal Staging
14. MA18.09 Carboplatin, Etoposide, Bevacizumab, and Atezolizumab in Patients with Extensive-Stage SCLC - GOIRC-01-2019 CeLEBrATE Trial
15. 1994P Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
16. Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL
17. 205P Modelling of NSCLC aPD1 responses in bronchoscopc biopsies on chip (bronchoBOCs)
18. EP14.01-006 CeLEBrATE: Phase II trial of CarbopLatin, Etoposide, Bevacizumab and Atezolizumab in Patients with exTEnsive-Stage SCLC-GOIRC-01-2019
19. EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)
20. EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial
21. EP02.04-001 Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)
22. 1041P Efficacy and safety of chemotherapy after progression on immunotherapy: Results of a multicenter retrospective observational trial
23. 10P Family history of cancer correlates with improved outcome from immunotherapy in NSCLC independent of somatic DNA damage response gene status
24. 117P Family history of cancer and improved outcomes with first-line immunotherapy in NSCLC patients
25. LBA82 Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal challenge): A FICOG study
26. EP1.04-02 Predictors of Lung Toxicity in First Line Pembrolizumb for Advanced NSCLC: An Interim Analysis of PRELUTOX Study
27. P1.18-21 Short and Mid-Term Outcomes of Multimodal Treatment for Locally-Advanced Non Small Cell Lung Cancer in Elderly Patients
28. 1568P - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
29. 1561P - Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: A study on circulating tumour DNA
30. P3.17-09 Retrospective Analysis of the Efficacy and Safety of Multimodal Treatment for Locally-Advanced NSCLC in Elderly Patients
31. 184P Clinico-radiological pattern of response to nivolumab in stage IV NSCL: A real life experience over two years
32. 58P - Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study
33. Atypical presentation of celiac disease in paediatric patients: Clinical rationale of the screening in individuals with chronic constipation
34. Childhood functional constipation: Evaluation and treatment
35. R41 - Physical exercise and eating habits in cancer survivors
36. H52 - Pemetrexed maintenance therapy in advanced non-squamous NSCLC: a single institution experience
37. A64 - Fast Walking And Resistance Exercise Program In Breast Cancer Survivors
38. 1646PD - Customized First Line Chemotherapy According to ERCC1 and RRM1 SNPS in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients: A Phase II Study
39. 9136 Erlotinib as a second-line therapy in advanced non small cell lung cancer: correlation between clinical characteristics and biomarkers
40. Gemcitabine—Cisplatin chemotherapy followed by radiotherapy in locally advanced non-small cell lung cancer (nsclc): A phase II retrospective analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.